| Literature DB >> 29682584 |
Mohammed J Alramadan1, Afsana Afroz1, Sultana Monira Hussain1, Mohammed Ali Batais2, Turky H Almigbal2, Hassan Ahmad Al-Humrani3, Ahmed Albaloshi4, Lorena Romero5, Dianna J Magliano1,6, Baki Billah1.
Abstract
The aim of this systematic review is to assess patient-related factors affecting glycaemic control among people with type 2 diabetes in the Arabian Gulf Council countries. MEDLINE, Embase, PsycINFO, CINAHL, and Cochrane CENTRAL databases were searched from their date of inception to May 2016. Two researchers independently identified eligible studies and assessed the risk of bias. A total of 13 studies met the inclusion criteria. One study was population based, six recruited participants from multiple centres, and the remaining were single centred. The majority of the studies were of low to moderate quality. Factors associated with poor glycaemic control include longer duration of diabetes, low level of education, poor compliance to diet and medication, poor attitude towards the disease, poor self-management behaviour, anxiety, depression, renal impairment, hypertension, and dyslipidaemia. Healthcare providers should be aware of these factors and provide appropriate education and care especially for those who have poor glycaemic control. Innovative educational programs should be implemented in the healthcare systems to improve patient compliance and practices. A variation in the results of the included studies was observed, and some potentially important risk factors such as dietary habits, physical activity, family support, and cognitive function were not adequately addressed. Further research is needed in this area.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29682584 PMCID: PMC5845488 DOI: 10.1155/2018/9389265
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Quality assessment tool for observational cohort and cross-sectional studies.
| Criteria | Yes | No | Others (CD, NR, and NA)∗ |
|---|---|---|---|
| (1) Was the research question or objective in this paper clearly stated? | |||
| (2) Was the study population clearly specified and defined? | |||
| (3) Was the participation rate of eligible persons at least 50%? | |||
| (4) Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | |||
| (5) Was a sample size justification, power description, or variance and effect estimates provided? | |||
| (6) For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | |||
| (7) Was the time frame sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | |||
| (8) For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure or exposure measured as continuous variable)? | |||
| (9) Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | |||
| (10) Was the exposure(s) assessed more than once over time? | |||
| (11) Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | |||
| (12) Were the outcome assessors blinded to the exposure status of participants? | |||
| (13) Was loss to follow-up after baseline 20% or less? | |||
| (14) Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | |||
|
| |||
| Quality rating (good, fair, or poor) (see guidance) | |||
| Rater no. 1 initials: | |||
| Rater no. 2 initials: | |||
| Additional comments (if poor, please state why): | |||
∗CD: cannot determine; NA: not applicable; NR: not reported.
Quality assessment of case-control studies.
| Criteria | Yes | No | Others (CD, NR, and NA)∗ |
|---|---|---|---|
| (1) Was the research question or objective in this paper clearly stated and appropriate? | |||
| (2) Was the study population clearly specified and defined? | |||
| (3) Did the authors include a sample size justification? | |||
| (4) Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same time frame)? | |||
| (5) Were the definitions, inclusion and exclusion criteria, algorithms, or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? | |||
| (6) Were the cases clearly defined and differentiated from controls? | |||
| (7) If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? | |||
| (8) Was there use of concurrent controls? | |||
| (9) Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? | |||
| (10) Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? | |||
| (11) Were the assessors of exposure/risk blinded to the case or control status of participants? | |||
| (12) Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis? | |||
|
| |||
| Quality rating (good, fair, or poor) (see guidance) | |||
| Rater no. 1 initials: | |||
| Rater no. 2 initials: | |||
| Additional comments (if poor, please state why): | |||
∗CD: cannot determine; NA: not applicable; NR: not reported.
Figure 1Flow chart of the systematic literature search.
Included studies and their general features.
| Author | Study design population | Population | Number of participants (male and female) | Age (mean age ± SD) | Glycaemic control measurement method(s) | Risk factors examined | Instrument used to measure risk factors |
|---|---|---|---|---|---|---|---|
| Ajabnoor | Case-control | Diabetics attending King Abdulaziz University Hospital diabetic clinic | Cases 73 (23, 50) | — | HbA1c | Age, gender, FPG, and treatment modality | Questionnaire and lab test |
| Binhemd | Cross-sectional | Females attending Diabetes and Endocrine Centre in Dammam | 300 (0, 300) | 42.6 ± 9.1 | HbA1c | KAP (knowledge, attitude and practice), diabetes type, and diabetes duration | Interview using a questionnaire, anthropometric measures, and lab test |
| Al-Nuaim | Cross-sectional | National (different regions of SA) | 613 (320, 293) | Good control 47.0 ± 14.8 | RBG | Age, BMI, region, residency, gender, and treatment modalities | Interview using a questionnaire, anthropometric measures, and lab test |
| Malik | Cross-sectional | Patients attending Mafraq Hospital in Abu Dhabi and its surrounding health clinics | 696 | — | FPG | Age, gender, ethnicity, diabetes duration, family history, treatment modalities, and follow-up location | Interview using a questionnaire and lab test |
| Abdelmoneim | Cross-sectional | Patients attending diabetic clinic in a primary healthcare centre | 198 (90, 108) | Males 59.5 ± 8.9 | FPG | Age, gender, family history, diabetes duration, BMI, cholesterol level, complications, number of health education session, and crowding index | Review of medical records |
| Al-Kaabi | Cross-sectional | Diabetic patients attending outpatient clinic at Tawam Hospital and primary healthcare centres in Al Ain district | 409 (158, 251) | 51.4 ± 11.2 | HbA1c | Age, gender, marital status, level of education, occupation, smoking, eating practice, BMI, abdominal circumference, blood pressure, and lipid profile | Interviewer-administered questionnaire and anthropometric measures. Blood tests from medical records |
| Al-Kaabi | Cross-sectional | Diabetic patients attending outpatient clinic at Tawam Hospital and primary healthcare centres in Al Ain district | 309 (68, 241) | 52 ± 9.9 | HbA1c | Age, gender, nationality, marital status, level of education, employment, income, diabetes duration, smoking, diabetes complications, physical activity, BMI, abdominal circumference, and blood pressure | Interviewer-administered questionnaire and anthropometric measures. Blood tests from medical records |
| Al-Lawati | Cross-sectional | Multicentred (different regions of Oman) | 1266 (570, 696) | 53.3 ± 11.5 | HbA1c | Age, gender, duration of diabetes, treatment modalities, BMI, eGFR, smoking, and healthcare index | Data collected from patients' medical records |
| Al-Hayek | Cross-sectional | Patients attending Sultan Bin Abdulaziz Humanitarian City, Riyadh | 147 (99, 48) | 57.3 ± 14.4 | HbA1c | Age, gender, marital status, employment, BMI, self-care management behaviour, self-monitoring of blood glucose, medication adherence, anxiety, and depression | Interviewer-administered questionnaire and anthropometric measures. Blood tests from medical records |
| Shamsi | Cross-sectional | Patients attending 5 healthcare centres in Bahrain | 400 (192, 208) | 54.7 ± 9.95 | HbA1c | Dietary practice | Interviewer-administered uestionnaire. Anthropometric measures and blood tests results were collected from medical records |
| Al Balushi | Cross-sectional | Type 2 patients attending Al Dakhliya region primary healthcare centre | 177 (71, 106) | 53 ± 12 | FBG | Age, gender, diabetes duration, BMI, blood pressure, creatinine, and lipid profile | Data collected from patients' medical records |
| Alrahbi | Cross-sectional | Patients attending 35 healthcare centres in Muscat and Al Dakhliya | 266 (121, 145) | — | HbA1c | Diabetes self-management | Self-administered questionnaire and blood test for HbA1c |
| D'Souza | Cross-sectional | Patients attending diabetic clinic at a public hospital in Oman | 300 (143, 157) | — | HbA1c | Age, gender, education, diabetes duration, diabetes education, medication, and BMI | Interviewer-administered questionnaire and patient's medical records for HbA1c |
HbA1c: haemoglobin A1c; FPS: fasting plasma sugar; eGFR: estimated glomerular filtration rate; TTT: treatment.
Risk of bias for the included studies.
| Study | Criteria 1 | Criteria 2 | Criteria 3 | Criteria 4 | Criteria 5 | Criteria 6 | Criteria 7 | Criteria 8 | Criteria 9 | Criteria 10 | Criteria 11 | Criteria 12 | Criteria 13 | Criteria 14 | Overall quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case-control | |||||||||||||||
| Ajabnoor | Yes | Yes | No | No | NR | Yes | No | NR | Yes | Yes | No | No | — | — | Low |
| Cross-sectional | |||||||||||||||
| Binhemd | Yes | Yes | NR | Yes | No | NA | NA | No | Yes | NA | Yes | NA | NA | No | Low |
| Al-Nuaim | Yes | Yes | NR | Yes | No | NA | NA | Yes | Yes | NA | Yes | NA | NA | Yes | High |
| Malik | Yes | No | NR | Yes | No | NA | NA | Yes | Yes | NA | Yes | NA | NA | No | Low |
| Abdelmoneim | Yes | Yes | NR | Yes | No | NA | NA | No | Yes | NA | Yes | NA | NA | Yes | Moderate |
| Al-Kaabi | Yes | Yes | NR | Yes | No | NA | NA | No | No | NA | Yes | NA | NA | Yes | Moderate |
| Al-Kaabi | Yes | Yes | NR | Yes | No | NA | NA | Yes | Yes | NA | Yes | NA | NA | No | High |
| Al-Lawati | Yes | Yes | NR | Yes | No | NA | NA | Yes | Yes | NA | Yes | NA | NA | Yes | Moderate |
| Al-Hayek | Yes | Yes | NR | Yes | No | NA | NA | Yes | Yes | NA | Yes | NA | NA | No | Low |
| Shamsi | Yes | Yes | NR | Yes | No | NA | NA | Yes | Yes | NA | Yes | NA | NA | No | Moderate |
| Al Balushi | Yes | Yes | NR | Yes | No | NA | NA | Yes | Yes | NA | Yes | NA | NA | No | Low |
| Alrahbi | Yes | Yes | NR | Yes | No | NA | NA | Yes | Yes | NA | Yes | NA | NA | No | Low |
| D'Souza | Yes | Yes | NR | Yes | Yes | NA | NA | Yes | Yes | NA | Yes | NA | NA | No | Low |
NR: not reported; NA: not applicable.
Results of the included studies.
| Author | Risk factors examined | Risk factors associated with glycaemic control | Statistical analysis of positive results | Main conclusion | ||||
|---|---|---|---|---|---|---|---|---|
| Ajabnoor | Age, gender, duration of diabetes, FPG, and treatment modality | FPG and treatment modalities | FPG/HbA1c correlation | HbA1c is associated with FBG and treatment modality but not with age, gender, and duration of diabetes | ||||
| Treatment modality | Mean HbA1c |
| ||||||
| Insulin | 14.3 ± 1.3 | |||||||
| Oral | 17.0 ± 0.0 | <0.001 | ||||||
| Diet | 16.3 ± 1.8 | 0.02 | ||||||
|
| ||||||||
| Binhemd | Knowledge, attitude and practice (KAP), diabetes type, and diabetes duration | KAP and diabetes duration | Positive correlation between HbA1c and diabetes duration ( | The positive correlation between HbA1c and the patients' practice and attitude reflects the need for continuous patient education, follow-up, and support | ||||
|
| ||||||||
| Al-Nuaim | Age, BMI, region, residency, gender, and treatment modalities | TTT modalities | Adjusted odds ratio and 95% confidence interval (95% CI) of poor glycaemic control | There is a significant relation between glycaemic control and treatment modalities | ||||
| TTT modality (ref: diet regimen) | ||||||||
| Odds ratio | 95% CI |
| ||||||
| Oral agent | 1.7 | 1.1–2.6 | 0.005 | |||||
| Insulin | 2.6 | 1.4–5.0 | ||||||
|
| ||||||||
| Malik | Age, gender, ethnicity, diabetes duration, family history, treatment modalities, and follow-up location | Duration of diabetes, follow-up location, and family history | Control | Odds ratio ( | Improvements are needed in primary care and in the community-based approach to diabetes control | |||
| Fair | Poor | |||||||
| Diabetes duration (years) | 1.03 (0.329) | 1.08 (0.007) | ||||||
| Follow-up at health centres (ref: hospital) | 1.86 (0.036) | 2.47 (0.001) | ||||||
| Family history (ref: none) | 0.62 (0.095) | 0.39 (0.001) | ||||||
|
| ||||||||
| Abdelmoneim | Age, gender, family history, diabetes duration, BMI, cholesterol level, complications, number of health education session, and crowding index | Gender and health education | Odds ratio ( | Female sex is a significant predictor of poor glycaemic control, and among females, the lower the number of education sessions, the poorer the diabetes control | ||||
| Gender (ref: male) | 2.84 (<0.05) | |||||||
| Health education among females | 0.28 (<0.05) | |||||||
| Health education among males | 1.39 (<0.05) | |||||||
| Al-Kaabi | Age, gender, marital status, level of education, occupation, smoking, eating practice, BMI, abdominal circumference, blood pressure, and lipid profile | Carbonated drinks age | Regression analyses of HbA1c level (adjusted beta coef. ( | The dietary practice of people with diabetes in the UAE is inadequate and needs improvement | ||||
| Number of carbonated drinks | 0.201 (0.029) | |||||||
| Age | 0.023 (0.047) | |||||||
|
| ||||||||
| Al-Kaabi | Age, gender, nationality, marital status, level of education, employment, income, diabetes duration, smoking, diabetes complications, physical activity, BMI, abdominal circumference, and blood pressure | No significant association | Multiple regression analysis of HbA1c in relation to age, gender, education, duration of diabetes, and physical activity did not reveal any significant association | The physical activity practice of people with diabetes in the UAE is largely inadequate to meet the recommendations | ||||
|
| ||||||||
| Al-Lawati | Age, gender, duration of diabetes, treatment modalities, BMI, eGFR, smoking, and healthcare index | Age, gender, eGFR, diabetes duration, and TTT modalities | Adjusted odds ratio and | Younger Omani adults exhibit worse glycaemic levels compared to older adults | ||||
| Age (ref: 20–39 yrs) | 40–59 yrs | 1.7 | 0.01 | |||||
| 60+ yrs | 2.5 | 0.0001 | ||||||
| Sex (ref: men) | Women | 1.5 | 0.001 | |||||
| Diabetes duration (ref: <5 yrs) | ≥5 yrs | 0.8 | 0.041 | |||||
| Treatment type (ref: diet) | Oral | 0.2 | 0.001 | |||||
| Insulin ± oral | 0.1 | 0.001 | ||||||
| eGFR (ref: <60 ml/min/1.73 m2 | ≥60 ml/min | 1.9 | 0.001 | |||||
|
| ||||||||
| Al-Hayek | Age, gender, marital status, employment, BMI, self-care management behaviour, self-monitoring of blood glucose, medication adherence, anxiety, and depression | Medication adherence, anxiety, and depression | HbA1c < 7% | HbA1c ≥ 7% |
| Poor diabetes self-care management behaviour, low adherence to medicine, and higher level of anxiety and depression are associated with poor glycaemic control | ||
| Medication adherence | 7.4 ± 1.4 | 5.4 ± 1.2 | 0.0007 | |||||
| Anxiety | 7.9 ± 1.3 | 10.3 ± 1.7 | 0.0005 | |||||
| Depression | 6.9 ± 0.9 | 9.8 ± 1.3 | 0.0002 | |||||
| Total hospital anxiety and depression scale (HADS) | 14.8 ± 1.8 | 20.1 ± 2.1 | 0.0001 | |||||
|
| ||||||||
| Shamsi | Dietary practice | Dietary practice | Dietary practice | HbA1c (mean ± SD) |
| There is a significant relation between the dietary practice and the HbA1c level | ||
| Very poor | 10.95 ± 1.56 | 0.006 | ||||||
| Poor | 7.46 ± 1.74 | |||||||
| Average | 7.46 ± 1.97 | |||||||
| Good | 7.31 ± 2.07 | |||||||
| Very good | 5.97 ± 1.36 | |||||||
| Al Balushi | Age, gender, diabetes duration, BMI, blood pressure, creatinine, and lipid profile | Total cholesterol, diastolic blood pressure, and LDL | HbA1c < 7% | HbA1c ≥ 7% |
| There is a significant association between HbA1c and diastolic blood pressure, total cholesterol, and LDL | ||
| Diastolic blood pressure, mmHg (mean ± SD) | 80 ± 8 | 84 ± 9 | 0.006 | |||||
| Total cholesterol, mmol/l (mean ± SD) | 4.7 ± 0.8 | 5.2 ± 1.3 | 0.002 | |||||
| LDL, mmol/l (mean ± SD) | 3.0 ± 1.2 | 3.8 ± 1.0 | 0.034 | |||||
|
| ||||||||
| Alrahbi | Diabetes self-management | No association between diabetes self-management and glycaemic control was found | No association was found | There is no association between diabetes self-management and glycaemic control | ||||
|
| ||||||||
| D'Souza | Age, gender, education, diabetes duration, diabetes education, medication, BMI, and patient empowerment | Age, education, diabetes duration prior to diabetes education, TTT modalities empowerment, effect of diabetes on activities of daily living | HbA1c < 7% | HbA1c ≥ 7% |
| Interventions to increase the empowerment of people with T2DM should be made for better glycaemic control | ||
| Age (no. (%)) | 30–39 yrs | 24 (51.1) | 23 (48.9) | 0.000 | ||||
| 40–49 yrs | 52 (50.5) | 51 (49.5) | ||||||
| 50–59 yrs | 36 (39.1) | 56 (60.9) | ||||||
| ≥60 yrs | 26 (44.8) | 32 (55.2) | ||||||
| Education (no. (%)) | Until 8th grade | 56 (47.9) | 61 (52.1) | 0.000 | ||||
| High school | 51 (54.3) | 43 (45.7) | ||||||
| Diploma/tech | 31 (10.3) | 58 (67.4) | ||||||
| Duration of diabetes (no. (%)) | 0–9 yrs | 57 (50.9) | 55 (49.1) | 0.000 | ||||
| 10–19 yrs | 68 (47.2) | 76 (52.8) | ||||||
| ≥20 yrs | 13 (29.5) | 31 (70.5) | ||||||
| Diabetes education program (no. (%)) | No | 54 (47.0) | 61 (53.0) | 0.000 | ||||
| Yes | 84 (45.4) | 101 (54.6) | ||||||
| Medications (no. (%)) | Oral | 109 (50.5) | 107 (49.5) | 0.000 | ||||
| Insulin and oral | 29 (34.5) | 55 (65.5) | ||||||
| Regression analysis | ||||||||
| Empowerment and glycaemic control | Beta coef. |
| ||||||
| 0.657 | 0.001 | |||||||
HbA1c: haemoglobin A1c; FPS: fasting plasma sugar; eGFR: estimated glomerular filtration rate; TTT: treatment; ref: reference.